Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 133Brain Neoplasms 129Prostatic Neoplasms 108Neoplasm Metastasis 88Lung Neoplasms 74Carcinoma, Hepatocellular 71Pancreatic Neoplasms 69Breast Neoplasms 50Melanoma 44Carcinoma, Renal Cell 36Neoplasms 34Colorectal Neoplasms 26Squamous Cell Carcinoma of Head and Neck 25Glioblastoma 24Liver Neoplasms 20Head and Neck Neoplasms 17Small Cell Lung Carcinoma 15Sarcoma 13Kidney Neoplasms 13Glioma 12Urinary Bladder Neoplasms 10Recurrence 9Gliosarcoma 8Ovarian Neoplasms 7Central Nervous System Neoplasms 7Adenocarcinoma of Lung 7Adenocarcinoma 7Radiation Injuries 6Prostate Cancer Metastatic 6Neuroma, Acoustic 6

Interventions

luprolide acetate gel depot 1enzalutamide 1Triptorelin Pamoate 1Radiosurgery 1Leuprolide 1Goserelin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Castration-resistant Prostate Cancer Patients with Oligometastases × Radiosurgery × Clear all
NCT02685397 2024-12-04

PCS IX

Sir Mortimer B. Davis - Jewish General Hospital

Phase 2/3 Active not recruiting
102 enrolled
Genitourinary

Castration-resistant Prostate Cancer Patients with Oligometastases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡